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Abstract
Spinocerebellar Ataxia Type 2 (SCA2) is caused by expansion of a polyglutamine encoding triplet repeat in the human
ATXN2 gene beyond (CAG)31. This is thought to mediate toxic gain-of-function by protein aggregation and to affect RNA
processing, resulting in degenerative processes affecting preferentially cerebellar neurons. As a faithful animal model, we
generated a knock-in mouse replacing the single CAG of murine Atxn2 with CAG42, a frequent patient genotype. This
expansion size was inherited stably. The mice showed phenotypes with reduced weight and later motor incoordination.
Although brain Atxn2 mRNA became elevated, soluble ATXN2 protein levels diminished over time, which might explain
partial loss-of-function effects. Deficits in soluble ATXN2 protein correlated with the appearance of insoluble ATXN2, a
progressive feature in cerebellum possibly reflecting toxic gains-of-function. Since in vitro ATXN2 overexpression was known
to reduce levels of its protein interactor PABPC1, we studied expansion effects on PABPC1. In cortex, PABPC1 transcript and
soluble and insoluble protein levels were increased. In the more vulnerable cerebellum, the progressive insolubility of
PABPC1 was accompanied by decreased soluble protein levels, with PABPC1 mRNA showing no compensatory increase. The
sequestration of PABPC1 into insolubility by ATXN2 function gains was validated in human cell culture. To understand
consequences on mRNA processing, transcriptome profiles at medium and old age in three different tissues were studied
and demonstrated a selective induction of Fbxw8 in the old cerebellum. Fbxw8 is encoded next to the Atxn2 locus and was
shown in vitro to decrease the level of expanded insoluble ATXN2 protein. In conclusion, our data support the concept that
expanded ATXN2 undergoes progressive insolubility and affects PABPC1 by a toxic gain-of-function mechanism with tissue-
specific effects, which may be partially alleviated by the induction of FBXW8.
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Introduction
Spinocerebellar Ataxia Type 2 (SCA2) is one of 9 currently
known inherited neurodegenerative diseases (e.g. Huntington’s
disease, SCA1, SCA3, SBMA) that are caused by an expanded
CAG trinucleotide repeat within the coding region of the disease
gene, which expands its size from generation to generation and is
translated to a polyglutamine (polyQ) domain [1–4]. More than
90% of the human population carry a repeat size of 22–23 triplets
in the Ataxin-2 (ATXN2) gene [3], while alleles between 27 and 33
are considered intermediate size expansions and were recently
shown to result in a higher risk for related neurodegenerative
diseases such as ALS and Parkinsonism [5–7]. Individuals having a
polyQ-repeat of 32 CAGs or more may develop SCA2 [8], with
larger repeat sizes resulting in a more severe disease course and
earlier manifestation. Clinical disease onset occurs usually in late
adult life [9–11].
The clinical manifestations of all Spinocerebellar Ataxias are
similar, making the molecular genotyping indispensable to
establish diagnosis [8]. Increased appetite with subsequent loss of
subcutaneous fat and of weight are peripheral tissue features in
other polyQ neurodegenerative diseases such as Huntington’s
disease [12,13] and are also common in SCA2 patients [8,14]. The
primary characteristic manifestation in SCA2 patients reflects
cerebellar incoordination signs like gait/stance/limb ataxia,
dysarthria, dysmetria, adiadochokinesia, action tremor and
hypotonia. Besides, the thalamus, brainstem, cranial nerves, spinal
cord and muscles are affected early on, leading to a relatively
characteristic manifestation with reduced saccade velocity, altered
sleep, reduced deep tendon reflexes and cramps [15–23]. Early
involvement of the midbrain can also lead to a manifestation as
Parkinsonism [24,25]. Degeneration of the basal ganglia and the
precerebellar nuclei is also present, while the affection of the
cerebral cortex occurs relatively late [15,26]. Parkinsonism is also
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generally the same vulnerability pattern was observed, but
relatively early affection of the retina, the oculomotor, reticuloteg-
mental, facial, lateral vestibular, raphe interpositus nuclei in the
brainstem and some pyramidal cells in the primary motor cortex
was reported [27–29]. Therapy is mostly palliative, but a
surprising effect of deep brain stimulation on tremor was reported
in one case [30]. In the end stage of disease, patients die mostly
from respiratory failure [8].
Microscopic SCA2 findings in the cerebellum include early loss
of the large Purkinje neurons, preceded by a reduction in their
dendritic arborisation and in the thickness of the molecular layer
where the synaptic contacts and neuronal processes are located
[15]. While pathological intranuclear inclusion bodies (NIIs)
containing polyQ aggregates in SCA2 are detectable only in a
minority of brainstem neurons and never in cerebellar Purkinje
neurons, cytoplasmic aggregates of ATXN2 were reported in
SCA2 patient brains and in a mouse mutant with Purkinje-cell
specific maximal transgenic overexpression of ATXN2 [31–33],
raising the question to what extent the formation of inclusion
bodies containing the insoluble disease protein is the driving force
in the neurodegenerative process of SCA2.
The expanded polyglutamine domain in other disease proteins
is thought to mediate pathogenesis mainly by a toxic gain-of-
function mechanism, in particular through aggregation of the
mutant protein [34]. Partial loss-of-function effects have also been
noted for polyQ disease proteins where the physiological function
can already be quantified [35–37]. The few facts known about the
function of ATXN2 suggest that it exerts its neurodegenerative
effects as part of protein-RNA complexes [5]. ATXN2 is involved
to some extent in trophic signalling [38]. Sequence analysis of
ATXN2 revealed a PAM2 motif that mediates direct binding with
the poly(A)-binding protein PABPC1 [39,40] and two Lsm motifs
that may be involved in RNA processing. In the mammalian cell
line HEK293, the reduced ATXN2 levels lead to increased
endogenous PABPC1 levels and vice versa [41]. ATXN2 protein
associates with polyribosomes [40] and is mainly localized at the
rough endoplasmic reticulum [42]. Furthermore, ATXN2 was
found to be part of and necessary for the formation of stress
granules (SGs), distinct foci within the cytoplasm, where untrans-
lated mRNAs are translationally inhibited during conditions of cell
stress [39,41]. The expression of ATXN2 in the cerebellum is
prominent in Purkinje neurons that comprise a small minority of
all cerebellar cells, but are conspicuous due to their large
cytoplasm and dendritic trees, and their exceptional content of
ribosomal machinery easily visualized in Nissl stains. In cortex the
expression of ATXN2 is widespread through neuron populations
of several layers (compare Allen brain atlas and reference [43]).
As a faithful animal model of SCA2, we now generated the first
ATXN2 polyQ knock-in mouse. While mice usually have 1 CAG
at the site of the human ATXN2 triplet repeat, the knock-in mice
were designed to carry 42 CAGs in this locus. Knock-in mice have
three distinct advantages over available models [44]. Firstly, the
preferential vulnerability of specific tissues can be investigated in
contrast to models employing heterologous promoters. For this
aim we chose to compare the cerebellum as an early, severely
affected tissue versus cerebral cortex where the neurons are lost
only at late stages and where cognitive signs originate only in few
patients. Secondly, in knock-in mice the contribution of partial
loss-of-function versus toxic gain-of-function effects can be studied,
in contrast to transgenic overexpressing animals or transfected
cells that model SCA2 through elevated dosage of ATXN2 DNA,
mRNA and protein. For this purpose, we performed a careful
evaluation of mutants from different litters in comparison to their
wild-type littermates, assessing systematically the endogenous
transcript levels, soluble protein and insoluble protein levels as
driven by the endogenous promoter. Thirdly, knock-in mice have
the advantage over knock-in cells that disease progression and
mutation effects can be studied over years. Towards this goal, we
decided to perform longitudinal observation from early adult life
(age 6 weeks) to multimorbid senescence (age 21 months) and to
document the progressive effects of the ATXN2 expansion on
PABPC1. We chose PABPC1 as a direct protein interactor of
ATXN2, which relocalizes together with ATXN2 under cell stress
from the rER to SGs, is controlled in its protein level by the
physiological function of ATXN2, and has a well studied cellular
role in RNA processing. The data observed indicate selective and
progressive pathology of cerebellar tissue regarding ATXN2
insolubility, PABPC1 deficiency, FBXW8 upregulation and
locomotor impairment.
Results
The Repeat Size of Atxn2-CAG42-Knock-In Mice Is Stably
Transmitted
We generated a mouse line that expresses expanded Atxn2 under
the control of the endogenous murine Atxn2 promoter (Figures S1
and S2, Table S1). To confirm the successful homologous
recombination, a PCR with CAG-repeat flanking primers was
performed on DNA tail biopsies (Figure 1A), the product sequence
verified and the introduction of the CAG42-repeat confirmed. To
test how the repeat is transmitted in the mice over successive
generations, the PCR-products from mice across nine generations
from WT, heterozygous (CAG1/CAG42) and homozygous
(CAG42) animals were subjected to fragment analysis and their
size was determined (Figure 1B). All products had the exact same
length. These data indicate that the knock-in mice have a repeat of
42 CAGs that is stably transmitted.
Author Summary
Frequent age-associated neurodegenerative disorders like
Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease are
being elucidated molecularly by studying rare heritable
variants. Various hereditary neurodegenerative disorders
are caused by polyglutamine expansions in different
proteins. In spite of this common pathogenesis and the
pathological aggregation of most affected proteins,
investigators were puzzled that the pattern of affected
neuron population varies and that molecular mechanisms
seem different between such disorders. The polyglutamine
expansions in the Ataxin-2 (ATXN2) protein are exceptional
in view of the lack of aggregate clumps in nuclei of
affected Purkinje neurons and well documented alter-
ations of RNA processing in the resulting disorders SCA2
and ALS. Here, as a faithful disease model and to overcome
the unavailability of autopsied patient brain tissues, we
generated and characterized an ATXN2-CAG42-knock-in
mouse mutant. Our data show that the unspecific,
chronically present mutation leads to progressive insolu-
bility and to reduced soluble levels of the disease protein
and of an interactor protein, which modulates RNA
processing. Compensatory efforts are particularly weak in
vulnerable tissue. They appear to include the increased
degradation of the toxic disease protein by FBXW8. Thus
the link between protein and RNA pathology becomes
clear, and crucial molecular targets for preventive therapy
are identified.
Atxn2-CAG42-Knock-In Mouse Model of SCA2
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Excellent Motor Coordination at Young Age to a Deficit
at Old Age
To investigate changes in body weight which frequently
accompany neurodegenerative diseases and in particular SCA2,
littermate mice with homozygous mutant or wild-type genotypes
(Figure S3) were weighed at regular intervals from postnatal day
10 onwards. Already at the age of 10 days, CAG42 mice had a
significant body weight reduction of 19.27% compared to wild-
type littermates (p=0.0002); a reduction of 13–22% remained
significant throughout their life span (20 days: p=0.0005; 6 weeks:
p=0.0015; 3 months: p=0.0025; 6 months: p=0.0196; 12
months: p=0.0141; 18 months: p=0.0265; 21 months:
p=0.0496). Still, the weight gain was similar in CAG42 and
WT. The body weight of CAG1/CAG42 was consistently, but
non-significantly less than WT (Figure 2A).
The knock-in mice did not show overt ataxic behaviour during
cage life. To assess the development of a cerebellar phenotype in
more detail, animals were placed on an accelerating rotarod
apparatus and their latency to fall was recorded. At 6 weeks, the
first time point tested, the latency to fall was 1.2-fold increased
(p=0.0096) in CAG42 mice in comparison to their wild-type
littermates. CAG1/CAG42 mice were performing equally well as
wild-types. At 3, 6 and 12 months, both CAG42 and CAG1/
CAG42 showed no difference to WT in their performance. At the
age of 18 months the CAG42 mice showed a significantly shorter
latency to fall (0.68-fold, p=0.0296) from the rotarod, while at 21
months significance was just missed (0.65-fold reduction,
p=0.062), probably due to the low number of animals remaining
alive and available for analyses. Thus, CAG42 at early adult age
performed better than WT, but at old age considerably worse in
this test paradigm with particular sensitivity for cerebellar
dysfunction, reflecting possibly an initial overcompensation
followed by late-onset pathology. CAG1/CAG42 mice even at
old age still performed similarly well as the WT mice (Figure 2B),
in keeping with other reports that mice homozygous for polyQ
expansion disease show a stronger phenotype than heterozygous
animals. Grip strength remained unchanged, indicating that motor
neuron pathology and paralysis are absent (data not shown). In
addition, footprint analysis did not show any differences between
WT and CAG1/CAG42 or CAG42 mice up to 21 months (data
not shown). As ATXN2 triplet repeat expansions in human can
also lead to Parkinson syndrome with impaired spontaneous
movement, the motor activity of mice in an open field was
recorded. Neither horizontal/vertical activity, total distance,
movement time, number of movements, number of stereotypy
counts, margin/centre distance nor margin/centre time were
consistently altered (data not shown). Consequently, there was no
motor hyperactivity to explain the reduced body weight of knock-
in animals. Since the Atxn2 knock-out mice show excessive weight,
the present data might be interpreted as evidence for a gain-of-
function effect of the Atxn2-CAG42-knock-in in peripheral tissues.
In summary, a permanent reduction of body weight and a late-
onset impairment of rota rod performance were the only apparent
phenotypes in CAG42 mice.
The Atxn2 mRNA Is Stable and Its Expression Is Elevated
in Cerebellum and Cortex
In order to verify that the homologous recombination event
does not interfere with Atxn2 expression and to assess the stability
of the expanded transcript, quantitative real-time RT-PCR
(qPCR) was performed in cerebellum and cerebral cortex. While
the cerebellar Atxn2 mRNA levels at 6 weeks of age were
unchanged, at 6 months (p=0.0146) and 18 months (p=0.0339)
they were significantly elevated to 1.07-fold levels. In the cortex,
the upregulation of Atxn2 mRNA expression was already
significant at 6 weeks (1.29-fold, p=0.0101) and stayed significant
at 6 months (1.16-fold, p=0.0005) and 18 months (1.16-fold,
p=0.0474). The transcript levels of the Ataxin-2 interactor Pabpc1
remained unchanged at all time points in cerebellum. In contrast,
in cortex an upregulation of Pabpc1 mRNA to 1.07-fold
Figure 1. The paternal and maternal transmission of the 42
CAG repeat is stable. (A) A CAG-repeat flanking PCR with one FAM-
labelled primer was performed. As expected, wild-type (WT) animals
showed one product at 94 bp, whereas heterozygotes (CAG1/CAG42)
showed an additional larger product. In homozygous mutant mice
(CAG42) only the larger product was detected. c: negative control. (B)
The exact PCR product size was confirmed by fragment length analysis.
The peak in the WT sample represents the 94 bp product, while the
217 bp peak appeared in CAG42 animals. Both peaks were detectable
in CAG1/CAG42 mice.
doi:10.1371/journal.pgen.1002920.g001
Atxn2-CAG42-Knock-In Mouse Model of SCA2
PLOS Genetics | www.plosgenetics.org 3 August 2012 | Volume 8 | Issue 8 | e1002920Figure 2. A constant weight reduction and a late-onset deficit in a cerebellar test paradigm. (A) Homozygous CAG42 mice had a reduced
body weight by birth up to the age of 21 months, while no change was observed in heterozygous CAG1/CAG42 mice in comparison to wild-type
littermates (n$14 per genotype). (B) Motor coordination was tested on an accelerating rotarod apparatus. An initially increased locomotor
performance at 6 weeks of age in the CAG42 mice was replaced by normal activity at 3, 6 and 12 months. At 18 and 21 months age, CAG42 mice
showed impaired motor coordination (until 18 months: n$14 per genotype, 21 months: n$6 per genotype).
doi:10.1371/journal.pgen.1002920.g002
Atxn2-CAG42-Knock-In Mouse Model of SCA2
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18 months, respectively (Figure 3). Thus, a mild but statistically
significant elevation of Atxn2 transcript became apparent during
adult life in cerebellum and even earlier in cortex, indicating that
the selection marker remaining in the Atxn2 genomic locus does
not impair Atxn2 transcription and that the presence of a CAG42
repeat in the Atxn2 transcript does not lead to its instability.
Abnormally elevated Pabpc1 mRNA levels became apparent only
in the cortex by 6 months, a noteworthy finding since previous in
vitro transient transfection studies [41] found the ATXN2 loss-of
function to increase PABPC1 levels.
The Soluble Protein Levels in Old Cerebellum and Cortex
Are Reduced for ATXN2 and Altered for PABPC1
We investigated the stability and steady-state levels of expanded
ATXN2 in extracts of proteins soluble in RIPA extraction buffer.
Expanded ATXN2 with 42 glutamines displayed slowed electro-
phoretic mobility in comparison to wild-type ATXN2 (Figure 4).
Both in cerebellum and cortex, a reduction of soluble ATXN2 was
detectable in the CAG42 mice. The levels were diminished in the
cerebellum consistently at 6 weeks (0.75-fold, p=0.1008), 6
months (0.77-fold, p=0.0808) and significantly reduced at 18
months (0.62-fold, p=0.0037). The reduction of levels in the
cortex missed significance at 6 weeks (0.86-fold, p=0.1553), but
became significant both at 6 months (0.55-fold, p=0.0046) and 18
months (0.75-fold, p=0.0344). As expected by the elevated Pabpc1
transcript levels, cortical soluble PABPC1 levels were elevated by
18 months (1.28-fold, p=0.0293). Curiously, however, cerebellar
soluble PABPC1 was significantly reduced already at 6 weeks
(0.82-fold, p=0.034) and again at 18 months (0.75-fold,
p=0.0235) (Figure 4). Thus, a reduction of soluble Q42-ATXN2
protein in spite of elevated transcript levels was a consistent finding
in both tissues at all ages, in keeping with a partial loss-of-function
and explaining the elevated PABPC1 transcription in the cortex.
However, selectively in the cerebellum PABPC1 soluble protein
was also reduced in absence of any compensatory mRNA
induction.
Progressive Insolubility of Q42-ATXN2 and PABPC1
To test whether increased insolubility of Q42-ATXN2 explains
the effects observed, proteins from the pellet after extraction of the
soluble proteins were further extracted with a harsher buffer from
6, 12 and 24 months old mice. Detection with the anti-ATXN2
antibody failed, possibly due to epitope masking. Detection with
the 1C2 antibody which recognizes polyQ tracts of at least 38
glutamines [45] was successful in revealing the expected band of
correct size which was not apparent in wild-type tissue and
exclusively appeared in mutant tissue. In the cerebellum a clear
increase of insoluble Q42-ATXN2 was detected, which was
significant at 12 (3.14-fold, p=0.0096) and 24 months (4.28-fold,
p=0.0002) in comparison to 6 months Q42-ATXN2. In the
cortex, however, an increase was not observed. Also, insoluble
PABPC1 protein levels in the cerebellum increased over time and
were significantly elevated at 24 months both in comparison to 24
months old WT (1.72-fold, p=0.0078) and to 6 months old
CAG42 tissue (1.9-fold, p=0.0357). More insoluble PABPC1 was
Figure 3. Atxn2 and Pabpc1 mRNA levels are elevated in specific ages and areas. In the cerebellum an Atxn2 mRNA elevation was not
detectable until 6 months, whereas the Pabpc1 transcript levels remained unchanged. In the cortex an Atxn2 mRNA elevation was already detected
by 6 weeks and Pabpc1 mRNA was upregulated by 6 months (n=9–16 animals/genotype/tissue).
doi:10.1371/journal.pgen.1002920.g003
Atxn2-CAG42-Knock-In Mouse Model of SCA2
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months old mice (1.464-fold, p=0.0812) and became significant
by 24 months in comparison to the WT of the same age (1.98-fold,
p=0.02) and also in comparison to 6 months old CAG42 mice
(2.036-fold, p,0.0001). In wild-type animals the levels of insoluble
PABPC1 levels remained similarly low over time (Figure 5A).
Thus, increased insolubility of Q42-ATXN2, particularly in the
old cerebellum, appears to sequester PABPC1 into insolubility and
may explain the decreased levels of soluble ATXN2 and PABPC1.
In order to test the interaction between ATXN2 and PABPC1
in cerebellum with an independent biochemical method,
ATXN2 was immunoprecipitated from wild-type, CAG42 and
ATXN2-knock-out tissue and the co-immunoprecipitation of
PABPC1 documented in immunoblots. Q42-ATXN2 pulled
down slightly more of PABPC1 than wild-type ATXN2
(Figure 5B). Beyond previous reports of association between
the two tagged recombinant transfected proteins, our data
demonstrate for the first time this interaction between the two
endogenous proteins in mammalian tissue. Thus, Q42-ATXN2
is likely to sequester PABPC1 into insolubility through direct
interaction.
ATXN2 and PABPC1 Are Sequestered into Visible
Aggregates
To investigate whether this insolubility process results in the
formation of visible cytoplasmic aggregates containing ATXN2, as
described in affected neurons during late stages of SCA2 patients,
immunohistochemistry on cerebellar brain sections was performed.
At all ages tested, 7, 14 and 24 months, 1C2-immunoreactivity was
purely nuclear in wild-type mice, while the presence of Q42-
ATXN2 resulted in additional cytoplasmic signals of Purkinje
neurons, starting discretely by 14 months age and becoming
stronger by 24 months (Figure 6A–6F). The specific and selective
ATXN2 immunoreactivity of Purkinje neurons could be success-
fully visualized by an unmasking technique, while remaining
undetectable in knock-out tissue (Figure S4). This ATXN2
immunoreactivity of Purkinje cells revealed a diffuse cytoplasmic
distribution in WT cerebellum, while it became discretely granular
at 14 months in individual Purkinje neurons and markedly granular
at 24 months in most Purkinje neurons of CAG42 mice (Figure 6G–
6L). In addition, the PABPC1-immunoreactivity was diffusely
cytoplasmic in WT mice, but became discretely granular in some
Purkinje neurons by 14 months and markedly granular in most
Purkinje neurons by 24 months of age (Figure 6M–6R). Nuclear
inclusion bodies were never detected. A decrease of the molecular
layer thickness or of the Purkinje cell number (data not shown), or a
reductionin the intensity ofCalbindin immunoreactivity (Figure S5)
was not observed even at the age of 24 months, suggesting that a
neurodegenerative processisnotyetdetectableatthisage.Thus,the
histological analysis supports the concept of progressive insolubility
and aggregation of Q42-ATXN2 as well as PABPC1 in the
cerebellar Purkinje neurons which are the prominent site of
pathology in human SCA2.
Insoluble Normal and Expanded ATXN2 In Vitro Drives
Endogenous PABPC1 into Insolubility
To confirm in vitro that insoluble expanded ATXN2 influences
the PABPC1 solubility, HeLa cells were transfected transiently
with CAG22-ATXN2 and CAG74-ATXN2 constructs. Success-
ful overexpression was verified by qPCR and Western blot. Over
200-fold elevated CAG22-ATXN2 and CAG74-ATXN2 mRNA
levels were accompanied by reduced PABPC1 transcript levels
(approximately 0.5-fold, p=0.0087 and p=0.0041) (Figure 7A),
while at the protein level (Figure 7B) a 7.2-fold (p=0.0374) and
6.7-fold (p=0.1667) excess of soluble Q22-ATXN2 or Q74-
ATXN2 was found, accompanied by a reduction of endogenous
soluble PABPC1 levels to 0.65-fold (p=0.0138 and p=0.002).
To assess the insoluble fractions of both proteins, the pellet after
the extraction of soluble proteins was dissolved and re-extracted
with more detergents. Overexpressed Q22-ATXN2 and Q74-
ATXN2 were strongly detectable, while endogenous ATXN2 in
the empty vector control transfection was practically undetect-
able. Endogenous PABPC1 levels in the insoluble protein
fraction were increased to 3.2-fold after both Q22-ATXN2
(p=0.0048) and Q74-ATXN2 (p=0.0184) overexpression.
These data corroborate our previous tissue data that insoluble
ATXN2 of either normal or expanded size sequesters its
interactor protein PABPC1 into insolubility and may thus
contribute to the reduction of soluble PABPC1 levels. They
are also in keeping with the previous in vitro reports [41] that the
increase in soluble ATXN2 levels leads to reduced PABPC1
expression levels.
Microarray Transcriptome Profiling at Medium and
Advanced Age Documents Selective Induction of FBXW8
in Old Cerebellum
Attempting a survey of the alterations in mRNA processing
underlying this progressive pathology, we used cerebellum,
brainstem and liver tissue from presymptomatic 6 months and
symptomatic 18 months old WT and CAG42 mice (3 versus 3
animals per young group, 4 versus 4 per old group) to perform
Affymetrix microarray transcriptome studies at a genome-wide
level. At the age of 6 months, statistical analysis with correction
for multiple testing after Benjamini-Hochberg demonstrated
that no mRNAs showed dysregulated levels with significance in
cerebellum and brainstem, whil eo n l yo n eg e n ew a sd i f f e r e n -
tially regulated in liver. This gene Cyp4a14,i sr e p r e s e n t e do n l y
by one oligonucleotide spot on the microarray. The Cyto-
chrome P-450 enzyme family has a known role in cholesterol
biosynthesis and the Cyp4a14 induction is a known response of
liver tissue to altered fat content [46]. Since fatty liver is a
feature already documented and molecularly investigated in
ATXN2-KO mice [47], we did not investigate this finding
further. At the age of 18 months, altered regulation was
significant after Benjamini-Hochberg correction for 20 genes in
cerebellum, 14 genes in brainstem and 30 genes in liver. Among
those, the dysregulation of 5 genes was recognized consistently
by more than one oligonucleotide microarray spot (Table 1).
Upon independent validation of the findings by qPCR with
commercial Taqman assays, the dysregulations of Acat1, Ifi27l1
and Lgals1 could not be reproduced in tissue from different
animals; in contrast, a significant downregulation of Adam1a in
cerebellum to 0.71-fold (p=0.0007) and brainstem to 0.73-fold
( p=0 . 0 0 1 )a sw e l la sas i g n ificant upregulation of Fbxw8 to 2.38-
fold (p,0.0001) in cerebellum were confirmed in this approach.
Adam1a encodes a disintegrin/metalloprotease and has an
established role for spermatogenesis and fertilization [48]. Thus,
its dysregulation might relate to the reduced fertility observed in
ATXN2-KO mice [47]. Fbxw8 encodes a WD-40 domain
containing member of the F-box protein family, which are
substrate-recognition mediators within a SCF (SKP1-CUL1-F-
box)-type ubiquitin-E3-ligase complex involved in the tagging of
phosphorylated target proteins to destine them for degradation
[49].
Atxn2-CAG42-Knock-In Mouse Model of SCA2
PLOS Genetics | www.plosgenetics.org 6 August 2012 | Volume 8 | Issue 8 | e1002920Figure 4. Soluble ATXN2 protein levels are reduced and PABPC1 levels change. In cerebellar tissue, a trend in ATXN2 reduction was
observed at 6 weeks and 6 months age, with significance in ATXN2 reduction being reached at 18 months of age. Also, a significant PABPC1
reduction was apparent in 6 weeks and 18 months old CAG42 mice in the cerebellum. In the cortex, a reduction of ATXN2 levels was observed in 6
weeks old animals as a trend and with significance from 6 months onwards. An elevation of PABPC1 levels became significant at 18 months of age
(n=10–12 mice/genotype/tissue).
doi:10.1371/journal.pgen.1002920.g004
Atxn2-CAG42-Knock-In Mouse Model of SCA2
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Reduces the Insoluble Levels of Expanded ATXN2 in a
Human Cell Line
To assess whether Fbxw8 induction on transcript level results in
elevated FBXW8 protein levels, Western blots in 18 months old
cerebellum of WT and CAG42 micewereperformed (Figure 8A). A
significant upregulation of FBXW8 to 1.75-fold (p=0.043) in
CAG42 mice was documented. Thus, elevated Fbxw8 mRNA and
protein levels characterize the cerebellar tissue of old CAG42 mice.
To further examine the questions whether the selective
upregulation of Fbxw8 in old CAG42 cerebellum reflects a
compensatory cellular response to pathology and whether this is
an efficient regulation to degrade expanded ATXN2 also in
humans, we assessed the effects of elevated FBXW8 protein on the
soluble and insoluble levels of human ATXN2 in vitro. HeLa cells
were transiently single and double transfected with CAG22-
ATXN2, CAG74-ATXN2 and FBXW8 (Figure 8B). Transfection
only with CAG22-ATXN2 or CAG74-ATXN2 in the soluble
Figure 5. Increased sequestration of PABPC1 by insoluble Q42-ATXN2 with age. (A) In the cerebellum, a progressive insolubility of Q42-
ATXN2 from 6 to 12 and 24 months was detectable. The solubility of PABPC1 decreased from 6 to 24 months of age. Insoluble Q42-ATXN2 levels did
not change in the cortex, however, the insolubility of PABPC1 increased over time in CAG42 mice. Insoluble PABPC1 levels in WT mice remained
stably low in both tissues. (n=3 mice/genotype/tissue). (B) In the soluble fraction, both wild-type and expanded ATXN2 were able to co-
immunoprecipitate PABPC1, with slightly more PABPC1 being pulled down in CAG42 mice.
doi:10.1371/journal.pgen.1002920.g005
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PLOS Genetics | www.plosgenetics.org 8 August 2012 | Volume 8 | Issue 8 | e1002920Figure 6. Immunohistochemistry of cerebellar Purkinje cells. At 7, 14 and 24 months age, the Purkinje cells showed a purely nuclear
distribution of large polyQ-domains as revealed by 1C2-staining in WT tissue, while an additional granular cytoplasmic staining pattern became
apparent at 14 and 24 months in knock-in tissue (A–F). ATXN2 immunoreactivity was diffusely distributed throughout the cytoplasm and
concentrated in the perinuclear region in WT tissue, while a more granular appearance was detected discretely at 14 and markedly at 24 months in
CAG42 mice (G–L). The expected diffuse cytoplasmic distribution of PABPC1 was documented in WT mice; whereas again a more granular staining
pattern in CAG42 mice appeared by 14 months (M–R).
doi:10.1371/journal.pgen.1002920.g006
Atxn2-CAG42-Knock-In Mouse Model of SCA2
PLOS Genetics | www.plosgenetics.org 9 August 2012 | Volume 8 | Issue 8 | e1002920Figure 7. Normal and expanded insoluble ATXN2 drives PABPC1 into insolubility. (A) Overexpression of CAG22-ATXN2 and CAG74-ATXN2
led to significantly decreased PABPC1 transcript levels. (B) Overexpressed Q22-ATXN2 or Q74-ATXN2 reduced endogenous soluble PABPC1 levels,
whereas endogenous insoluble PABPC1 levels were significantly increased in the presence of insoluble ATXN2 (n=3).
doi:10.1371/journal.pgen.1002920.g007
Atxn2-CAG42-Knock-In Mouse Model of SCA2
PLOS Genetics | www.plosgenetics.org 10 August 2012 | Volume 8 | Issue 8 | e1002920phase led to a 72-fold increase of Q22-ATXN2 (p=0.0098) or a
67-fold increase of Q74-ATXN2 (p=0.056) protein compared to
the control vector pCMV. Additional expression of the control
vector pReceiver did not reduce Q22-ATXN2 or Q74-levels
significantly (57-fold, p=0.64, and 40-fold p=0.51). A further
overexpression of FBXW8 reduced Q74-ATXN2-levels by a
factor 3.3 (p=0.23), while it did not markedly change Q22-
ATXN2 levels. In the insoluble fraction, transfection led to
elevated Q22-ATXN2 (126-fold, p,0.0001) and Q74-ATXN2
(59-fold, p,0.0001) levels. Additional expression of the empty
pReceiver vector reduced Q22-ATXN2 levels (82-fold, p=0.036)
and did not alter Q74-ATXN2 levels (57-fold, p=0.93). After
double transfection with FBXW8 and Q22-ATXN2 or Q74-
ATXN2, the levels of ATXN2 were again significantly elevated
(64-fold, p=0.0002 and 18-fold, p=0.005, respectively) compared
to the FBXW8+pCMV control. This elevated level was signifi-
cantly less high for expanded ATXN2 in comparison to the
control double transfection with pReceiver and CAG74-ATXN2
(p=0.028). Control immunodetection of the FBXW8 levels
demonstrated the successful overexpression to result in detectable
upregulation in soluble and insoluble fractions, and a curious
increase of FBXW8 insoluble protein levels in the presence of
ATXN2. These in vitro human data indicate that the upregulation
of FBXW8 reduces the insoluble levels selectively of expanded
ATXN2. Analogous double transfection experiments showed that
also the insoluble fraction of Q41-ATXN2 becomes slightly
reduced by FBXW8, but this effect did not become significant in
three independent experiments (Figure S6).
Discussion
We have generated and characterized the first knock-in mouse
modelling Spinocerebellar Ataxia Type 2. Since SCA2 is a late-
onset progressive disease with selective vulnerability of the
cerebellar Purkinje neurons, it is interesting that similar temporal
dynamics were observed for the insolubility of ATXN2 and for the
accompanying sequestration of PABPC1 in the knock-in cerebel-
lum. The progressively granular immunoreactivity of ATXN2 and
PABPC1 in Purkinje neuron immunohistochemistry supports the
concept of aggregate accumulation, and the in vitro and Co-IP data
confirm that excess ATXN2 becomes insoluble and recruits its
interactor PABPC1 into insolubility. Progressively granular
immunoreactivity of both proteins becomes apparent in increasing
numbers of cerebellar Purkinje neurons even before the onset of
the selectively cerebellar motor deficits. Probably this pathological
process of aggregation corresponds to the toxic gain-of-function
which was shown to drive disease progression in other polyQ
disorders. A gain-of-function of ATXN2 might also underlie the
reduced weight of the knock-in animals, since ATXN2 knock-out
mice are known to have excessive weight [47]. Specifically in
cerebellar tissue, the insolubility and sequestration led to a
deficiency in soluble PABPC1 levels, an effect that might result in
impaired RNA processing as well as protein synthesis [50] and
therefore possibly critical for the Purkinje neurons with their large
ribosomal machinery. Indeed, these molecular abnormalities
correlate temporally with the late-onsetappearance ofmotor deficit.
The depletion of PABPC1 was shown to prevent global protein
synthesis and to promote cell death in mammalian cells [50].
PABPC1 binds to the 39 poly(A) tail of mRNAs to mediate their
circularization which precedes ribosome recruitment and transla-
tion initiation [51]. Furthermore, PABPC1 is important for the
poly(A) shortening and nonsense-mediated decay of mRNAs in the
cytoplasm [52,53]. During the formation of stress granules,
PABPC1 and ATXN2 relocalize there together with translation-
ally repressed mRNA complexes [41]. Furthermore, ATXN2
could play a role in mRNA splicing, since it contains Lsm domains
and since it interacts with A2BP1/Fox1 which is a well established
splicing modulator [54,55]. Finally, ATXN2 might modulate
transcription itself, since it was shown to relocalize to the nucleus
and control its own expression [56]. Thus, there are multiple ways
how ATXN2 could modulate RNA processing, and indeed the
confirmed role of ATXN2 expansions in interaction with other
RNA binding proteins for motoneuron degeneration diseases
[5,6,57] indicates this to be a crucial aspect of ATXN2 effects. Our
present data support the concept that reduced levels of PABPC1
are associated with the cerebellar vulnerability in SCA2, and that
the pathogenesis might have similarities to the altered mRNA
processing in ALS, FXTAS and SMA [58]. Unfortunately, the
rates of mRNA translation and deadenylation cannot be directly
quantified in tissue, so further mechanistic analyses will have to
rely on in vitro studies.
Table 1. Differentially regulated mRNAs in CAG42 mice at the age of 18 months.







Acat1 9 C–D 1451271_PM_a_at — — 21.42 (0.0101)
1424183_PM_at — — 21.50 (0.0071)
1424182_PM_at — — 21.58 (0.0052)
Adam1a 5 F 1443378_PM_s_at 21.77 (0.0009) 21.47 (0.0009) —
1427790_PM_at 21.89 (0.0071) — —
Fbxw8 5 F 1426944_PM_at 2.55 (0.0077) — —
1436732_PM_s_at 2.51 (0.0095) — —
Ifi27l1 12 E 1452956_PM_a_at — — 3.27 (0.0273)
1454757_PM_s_at — — 3.20 (0.0213)
Lgals1 15 E 1419573_PM_a_at — — 2.27 (0.0165)
1455439_PM_a_at — — 2.14 (0.0459)
Genes with significant dysregulation and consistency between more than one oligonucleotide spot are shown (n=4 mice/genotype).
doi:10.1371/journal.pgen.1002920.t001
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PLOS Genetics | www.plosgenetics.org 11 August 2012 | Volume 8 | Issue 8 | e1002920Figure 8. Elevated FBXW8 diminishes specifically insoluble expanded ATXN2. (A) The protein levels of FBXW8 were significantly
upregulated in the cerebellum of 18 months old CAG42 mice compared to wild-type (n=9–11 mice/genotype). (B) Soluble levels of Q22-ATXN2 were
unchanged after FBXW8 overexpression, while for Q74-ATXN2 a slight reduction was apparent. With respect to insoluble levels, Q22-ATXN2 was
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PABPC1 insolubility and the ATXN2 gain-of-function led to
decreased soluble PABPC1 levels that did not elicit a compensa-
tory upregulation of PABPC1 transcript levels. This may simply be
due to a maximal PABPC1 expression level in cerebellar cells that
cannot be enhanced further. In contrast, in cortex tissue a
similarly progressive PABPC1 sequestration appeared overcom-
pensated in the face of elevated levels of PABPC1 transcript and
soluble protein. We speculate that the cause of this upregulated
cortical PABPC1 expression lies in a response to the deficiency in
soluble ATXN2, since PABPC1 levels were previously found in
vitro to correlate indirectly with ATXN2 levels [41]. This partial
loss of soluble ATXN2 was observed in spite of elevated mRNA
levels in a quite constant manner in all ages and brain regions.
This is particularly interesting, since in other polyQ neurodegen-
erative diseases some minor symptoms have clearly been attributed
to a partial loss-of-function mechanism. For example, polyQ
expansions in the androgen receptor lead to a partial loss-of-
function of this protein with subsequent testicular feminisation of
male patients, apart from the atrophy of spinobulbar motoneurons
which contain polyQ aggregates [59].
Our investigation into consequences of ATXN2 expansions for
mRNA levels in a genome-wide transcriptome survey demon-
strated a surprising scarcity of effects, with the notable exception of
the highly significant, reproducible and specific dysregulation in
the expression of two ATXN2 neighbour genes, Adam1a and
Fbxw8. The murine Atxn2 gene lies on chromosome 5 F (position
122,162–122,265 kbp), with Adam1a (position 121,969–
121,972 kbp) being positioned at a distance of ,190 kbp from
Atxn2, and Fbxw8 (position 118,515–118,606 kbp) being located at
a distance of ,3556 kbp from Atxn2. Three different hypotheses
may explain these transcription effects with specificity to the Atxn2
locus. Firstly, it is conceivable that the knock-in targeting approach
has modified the Atxn2 locus, but the facts that the selection
markers were almost completely removed and that this locus effect
was not detectable in the transcriptome data at 6 months age
argue against this notion. Secondly, notions have been discussed
that the abnormal DNA structure of a (CAG)-expansion could
exert a progressive influence on chromatin structure [60]; indeed,
polyglutamine expansions of the SCA7 disease protein, which is a
component of a histone acetyltransferase complex, was shown to
result in aberrant chromatin [61]. However, such effects were not
confined to the surrounding locus and represented random toxic
side-effects on unrelated proteins rather than an influence on the
disease protein and its function. Thirdly, it is possible that the
genes that surround the Atxn2 locus are interacting in a common
pathway and that feedback-mechanisms regulate their expression
in dependence on ATXN2 function. Our in vitro data that Fbxw8
upregulation may selectively reduce the levels of insoluble,
expanded ATXN2 argues in favour of the latter hypothesis. A
compensatory cellular effort that degrades the expanded and toxic
ATXN2 and counteracts its gain-of-function would help to
minimize the alterations of interactors with downstream conse-
quences, thus postponing the onset of pathology; therefore
FBXW8 represents a promising molecular target for neuropro-
tective approaches. FBXW8 was reported to control growth in
parallel to modulating insulin-like growth factor binding protein 1
levels [62]. As FBXW8 null mice are growth retarded [62], the
induction of FBXW8 at old age in the knock-in tissue could again
be interpreted as an effort to compensate the weight reduction
caused by CAG42-ATXN2. Furthermore, FBXW8 modifies
neuronal dendrite formation [63]. It is also noteworthy that
ATXN2 was observed to interact with the neuroprotective
ubiquitin E3 ligase PARKIN [64], and that FBXW7 (SEL-10) is
also known to interact with PARKIN [49]. It goes beyond the
scope of this manuscript to test whether FBXW8 or other
members of this protein family may also contribute to the
degradation of other polyglutamine-expansion disease proteins like
huntingtin and ataxin-1. Overall, the early induction of Cyp14a4
and the later induction of Fbxw8 are probably part of the cellular
stress response. In order to study further progression of the
neurodegenerative process beyond such early compensatory
efforts, and to understand later SCA2 and ALS stages, ATXN2
knock-in mice with larger CAG expansions or with CAA
interruptions may have to be studied.
In conclusion, our first report of a knock-in mouse with CAG42
to model SCA2 confirms that progressive insolubility of ATXN2
particularly in the cerebellum is the molecular feature which
correlates best with the late-onset motor incoordination. The
subsequent sequestration of the interactor protein PABPC1 into
insolubility provides a first insight from the analysis of brain tissue
for the recent focus how SCA2 and ALS pathogenesis might affect
RNA processing [65,66]. The cerebellar tissue differed from
cortical tissue by the lack of a compensatory upregulation of
PABPC1 expression. Specifically in cerebellar tissue at old age, an
upregulation of Fbxw8 levels was observed, which may contribute
to counteract the ATXN2 gain-of-function according to our
human in vitro studies. These findings may lead us to understand
the tissue specificity in this disease process. We believe that this
knock-in mouse will constitute a valuable tool for pathogenesis
research in early stages of SCA2 and possibly also ALS, given the
scarce availability of human autopsy brain tissues. Although the
ATXN2 triplet repeat is transmitted stably across generations in
mouse in contrast to humans, this may be an advantage for the
long term comparability of data from this knock-in model.
Materials and Methods
Generation of Atxn2-CAG42-Knock-In Mice
Atxn2-CAG42-knock-in mice were generated by modifying the
previously described pKO-Sca2-vector [47]. Exon 1 was deleted
via the unique restriction sites SgrAI and Eco47III and replaced
by a synthesized exon 1 fragment containing the CAG42-repeat
(custom-made by Geneart, Regensburg) at the amino acid position
glutamine 156, resulting in the targeting vector NOW1-HR. The
sequence verified vector was electroporated into 129Sv/Pas ES
cells to allow for homologous recombination at the endogenous
Ataxin-2 locus. Its integration was verified using PCR. The correct
39 integration was verified using a forward primer hybridizing in
the neomycin selection cassette and a reverse primer downstream
of the targeting vector homology sequence. Verification of the
correct 59 integration was achieved with a primer pair flanking the
loxP site. The forward primer was located upstream of the long
homology arm of the targeting vector and the reverse primer
hybridized upstream of the distal loxP site within the 59 homology
arm of the targeting vector. Additionally, the integration of the
CAG repeat insertion was verified using primers flanking the CAG
repeat. Further validation was performed by Southern blot
analysis (Figure S1). Removal of the FRT flanked neomycin
resistance cassette was performed via Flp-mediated excision and its
again not influenced by FBXW8 overexpression, while the Q74-ATXN2 reduction became significant. FBXW8 levels were significantly increased by its
overexpression both in the soluble and insoluble fraction (n=7).
doi:10.1371/journal.pgen.1002920.g008
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not shown). Correctly targeted ES cell clones were injected into
C57BL/6 blastocysts. This work was outsourced to Genoway
(Lyon, France). For primer sequences see Tables S2, S3, S4, S5.
Genotyping of the Atxn2-CAG42-Knock-In Mouse
DNA from tail biopsies was isolated and the genotyping PCR
was performed. TaKaRa LA Taq-Polymerase (Takara Bio Inc.,
Japan) was used to amplify the neomycin cassette excised locus
with the primer pair NOW1-K2 59-TGAGTTGACTCCA-
CAGGGAGGTGAGC-39 and NOW1-H2 59-CCATCTCGC-
CAGCCCGTAAGATTC-39 flanking this site. The conditions
were: initial denaturation at 94uC-39, followed by 30 cycles of
94uC-150 denaturation, 68uC-49 annealing and elongation and a
final elongation step at 68uC-99. The wild-type (WT) allele is
predicted to yield an amplification product of 793 bp and the
knock-in (CAG42) allele one of 984 bp, while heterozygous
(CAG1/CAG42) mice show products of both sizes (Figure S3).
Animals
Mice were housed in accordance with the German Animal
Welfare Act, the Council Directive of 24 November 1986 (86/
609/EWG) with Annex II and the ETS123 (European Conven-
tion for the Protection of Vertebrate Animals) at the FELASA-
certified Central Animal Facility (ZFE) of the Frankfurt University
Medical School. Mice were backcrossed from a mixed 129Sv/
Pas6C57BL/6 for at least 8 generations into the C57BL/6 strain.
Littermates derived from heterozygous matings were used for all
experiments.
Body Weight and Behavioural Observations
For behaviour observations, male and female mice were used in
similar proportions. Mice were weighed before behavioural
testing. The motor performance of mice was assessed using an
accelerating rotarod apparatus (Ugo Basile, Comerio, Robert &
Jones, model 7650). Mice from three founder lines were placed at
different ages on the accelerating rod (from 4–40 rpm) and latency
to fall was recorded during the 5 minute trial. Grip strength was
assessed by measuring the peak force of the fore limbs in 10 trials
per mouse on an electronic grip strength meter (TSE, Bad
Homburg). Footprints were evaluated by painting the hind limbs
of mice with a non-toxic ink. The mice were allowed to walk
through a paper lined tunnel (height: 6 cm6width: 9 cm6length:
40 cm) and step length, gait width, alternation coefficient and
linear movement were analyzed on the basis of the footprints as
described previously [67]. The spontaneous motor activity of the
mice was recorded by a Versamax animal activity monitor
(Accuscan, Columbus). The mouse was placed into the 20620 cm
arena and its activity recorded during the 5 minute trial.
Verification of the CAG Repeat Length
The determination of the CAG repeat length was done using
fragment analysis. The CAG repeat was amplified with TaKaRa
LA Taq-Polymerase (Takara Bio Inc., Japan) from DNA from tail
biopsies using a 59-FAM-labeled forward primer 59-
CCCCGCCCGGCGTGCGAGCCGGTGTAT-39 and the re-
verse primer 59-CGGGCTTGCGGCCAGTGG-39 under the
following conditions: 96uC-49, followed by 38 cycles of 94uC-19,
60uC-19 and 72uC-19 with a final elongation step at 72uC-79. The
determination of the fragment length was outsourced to
GENterprise GENOMICS (Mainz, Germany). Peak Scanner
Software 1.0 (Applied Biosystems) was used to determine the
exact PCR product size using the GS500 size standard.
RNA Isolation and Expression Analysis
After cervical dislocation the brain was removed, cerebellum and
cortex were dissected and quickly frozen in liquid nitrogen. RNA
extraction from tissue was performed with Trizol reagent (Invitro-
gen) and from cells using the RNeasy Mini Kit (Qiagen) according
to manufacturers’ instructions. For expression studies, 1 mg of total
RNA was digested with DNaseI Amplification Grade (Invitrogen)
and reversely transcribed using SuperScript III Reverse Transcrip-
tase (Invitrogen). Expression levels were investigated with a
StepOnePlus Real-Time PCR System (Applied Biosystems). cDNA
from 25 ng RNA were used in each PCR reaction with the
following TaqMan Assays (Applied Biosystems): Atxn2
(Mm01199894_m1, Hs00268077_m1), Pabpc1 (Mm00849569_s1,
Hs00743792_s1), Acat1 (Mm00507463_m1), Adam1a (Mm02581
738_s1), Fbxw8 (Mm00554876_m1), Ifi27l1 (Mm00835449_g1),
Lgals1 (Mm00839408_g1) and Tbp (Mm00446973_m1, Hs999
99910_m1) as endogenous control. The PCR conditions were
50uC-29,9 5 uC-109 followed by 40 cycles of 95uC-150 and 60uC-600.




50 mg of tissue were homogenized with a motor pestle in 10 vol.
RIPA buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Igepal CA-630 (Sigma), 0.5% sodium
deoxycholate, 0.1% SDS, 1 mM PMSF and one tablet Complete
Protease Inhibitor Cocktail (Roche)] followed by 15 minutes
incubation on ice. After centrifugation at 16,0006ga t4 uC for
20 minutes, the supernatant (soluble fraction) was preserved and
either 1/2 vol. Urea/SDS-buffer [8 M Urea, 5% SDS, 1 mM
PMSF, Complete protease inhibitor cocktail (Roche)] for tissue
extraction or 1/2 vol. 26 SDS-lysis buffer [137 mM Tris-HCl,
pH 6.8; 4% SDS; 20% glycerol] for cell extraction was added to
the pellet, sonicated and centrifuged at full-speed for 10 minutes.
The supernatant represented the insoluble fraction. Extracted
proteins were processed directly without freezing them. Protein
concentration was determined using the BCA protein assay kit
(Thermo Scientific). 10 or 20 mg of proteins were loaded and
separated on 8% polyacrylamide gels and transferred to PVDF
membranes. The membrane was blocked in 5% milk powder,
incubated with primary antibodies against Ataxin-2 (1:500, BD
Transduction Laboratories), PABPC1 (1:1000, Abcam), 1C2
(1:1000, Millipore), FBXW8 (1:750, Sigma) and b-Actin
(1:10,000, Sigma) and visualized using ECL method (Pierce).
Densitometric analysis was carried out using the ImageJ software.
Immunohistochemistry
The cerebellum of perfused (4% PFA) mouse brains was cut on
a microtome into 5 mm thick sagittal sections. For antibody
staining, sections were immersed for 30 minutes in 10% methanol,
3% H2O2 and 50 mM Tris (pH 7.6) and subsequently washed for
three times in Tris. Sections were blocked for 90 minutes with
0.25% Triton X, 0.1 M D-Lysine and 10% Tris-BSA. Blocking
before Ataxin-2 staining was modified using goat-serum in 0.1 M
PBS. Incubation with the primary antibodies against Ataxin-2 (BD
Transduction laboratories, 1:50), PABPC1 (Cell Signaling, 1:50),
1C2 (1:1000, Millipore) or Calbindin (1:3000) lasted 18 h at room
temperature. The biotinylated secondary antibody (1:200) was
applied for 90 minutes followed by incubation for 2 h in the
avidin-biotin-peroxidase complex (1:100 in Tris, ABC-Elite,
Vector Laboratories). Finally, sections were incubated in Tris with
0.07% DABand 0.001%H2O2. ForAtaxin-2 staining sections were
pretreated for 30 sec at 125uC in bull’s eye decloaker solution in a
decloaker chamber (Decloaker, Biocare Medical); for PABPC1
Atxn2-CAG42-Knock-In Mouse Model of SCA2
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staining the sections were incubated in the microwave 3 times for
10 minutes in Tris (pH 9.0), followed by a 3 minute incubation step
in 98% formic acid; for Calbindin staining the sections were
pretreated with trypsin. Determination of the molecular layer
thickness, Purkinje cell number and intensity of Calbindin
immunoreactivity were done by ImageJ in 2 mice/genotype with
at least 3 sections/animal and at least 10 microscopic fields/section.
Co-Immunoprecipitation
Approximately 50 mg of cerebellar tissue from 6 months old
animals were lysed in 106vol. lysis buffer (10 mM HEPES, 10 mM
KCl, 5 mM MgCl2, 0.1% Igepal CA-630 (Sigma), protease
inhibitors), incubated for 10 minutes at 4uC and subsequently
centrifuged for 20 minutes at 16,000 g. 200 mg of soluble proteins
derived from the supernatant were incubated overnight under
rotation with anti-ATXN2 antibody. Beads (Protein A/G-agarose,
Santa Cruz) were pre-treated overnight with washing buffer (0.2
NaCl, 1% gelatine, 0.05% NaN3, 50 mM Tris, 0.1% Triton) to
avoid unspecific protein binding. Antibody-protein complexes were
precipitated with beads under rotation for one hour at 4uC. Beads
were sedimented by centrifugation and washed for 4 times in PBS
including protease inhibitors and then subjected to Western blotting.
Cell Culture
HeLa cells were cultured in MEM medium (Invitrogen) with
10% FCS, 1% NEAA and 1% HEPES and seeded the day before
the experiment. 1 mg of the plasmids pCMV-Myc, ATXN2(-
CAG22)-Myc, ATXN2(CAG74)-Myc [38], FBXW8-pReceiver-
M55 (with Cherry-tag) and pReceiver-M56 (with Cherry-tag)
(Imagenes) were used for the transfection with Effectene Trans-
fection Reagent (Qiagen) according to manufacturer’s protocol.
Microarray Transcriptome Analysis
Cerebellum, brainstem and liver tissue from 6 and 18 months
old WT and CAG42 mice were sent to the MFT Services
(Tu ¨bingen, Germany) for analysis. The RNA was isolated, its
quality documented (one young CAG42 liver sample had to be
eliminated from analysis) and 100 ng of total RNA was amplified
with the Affymetrix 39 IVT Express Kit, labeled and hybridized
onto the mouse specific MOE430 2.0 Gene Chip (Affymetrix,
Santa Clara, CA, USA) that detects 39,000 transcripts and
variants corresponding to 34,000 mouse genes. Scanning of the
arrays was performed in the Gene Chip Scanner 3000 and the raw
data obtained with the AGCC 3.0 software. Further analysis was
done using the Bioconductor package (www.bioconductor.org).
RMA normalization was applied and calculation of differentially
expressed transcripts was done by compiling a linear model. F-
statistics was applied (empirical Bayes model) and the p-values
obtained were further corrected for multiple testing with the
‘‘Benjamini-Hochberg’’ test. P-values,0.05 were considered
significant. Genes that were detected within their exons and that
were dysregulated consistently according to more than one spot
were prioritized for further analysis. The original data from 18
months old animals have been deposited in NCBI’s Gene
Expression Omnibus [69] and are accessible through GEO Series
accession number GSE39640 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE39640) (NCBI tracking system
#16608301).
Statistical Analysis
The GraphPad Prism software version 4.03 (2005) and MS
Excel 2007 (Microsoft) were used to perform unpaired Student’s t-
test. Error bars indicate SEM. Values p,0.05 were considered
significant and marked with asterisks p,0.05 *, p,0.01
**, p,0.001 ***.
Supporting Information
Figure S1 Southern blot strategy for the detection of homolo-
gous recombination at the Atxn2 locus. Exon 1 is symbolized by a
hatched rectangle and the CAG repeat by a light grey rectangle.
FRT sites are represented by grey double triangles and loxP sites
by a single triangle. The expected DNA fragment sizes for the 59
Southern analysis are indicated in Table S1.
(TIF)
Figure S2 Targeting strategy for the generation of the Atxn2-
CAG42-knock-in model. Hatched rectangles represent Atxn2
coding sequences, light grey symbolizes the CAG42-repeat and a
solid line represents the chromosomal sequence. FRT sites are
represented by double triangles and LoxP sites by single triangles.
For primer sequences see Tables S2, S3, S4, S5.
(TIF)
Figure S3 Genotyping strategy. The genotyping strategy is
based on the distinction between the homologous recombined
Neo-excised knock-in (CAG42) allele (984 bp) and the wild-type
(WT) allele (793 bp). Heterozygotes (CAG1/CAG42) showed both
products.
(TIF)
Figure S4 Anti-ATXN2 immunohistochemistry of cerebellar
Purkinje cells in 5 months old wild-type and Ataxin-2 deficient
mice. Purkinje neurons of wild-type mice (WT) are selectively
visualized by Ataxin-2 staining, while they do not display the
specific immunoreactivity in Ataxin-2 deficient mice (KO).
(TIF)
Figure S5 Immunohistochemistry of cerebellar Purkinje cells in
24 months old wild-type and CAG42 mice. Calbindin immuno-
reactivity allowed the sensitive detection of Purkinje cell bodies
and dendritic trees, but an alteration of signal intensity or cell
numbers in mutant tissue was not detectable.
(TIF)
Figure S6 Overexpression of FBXW8 and CAG41-ATXN2 in
HeLa cells. The soluble levels of Q22-ATXN2 and Q41-ATXN2
were unchanged after FBXW8 overexpression. For the insoluble
levels, Q22-ATXN2 is again not influenced by FBXW8 levels,
while a slight but insignificant reduction may be apparent for Q41-
ATXN2, reminiscent of the stronger reduction for Q74-ATXN2
in Figure 8B. FBXW8 levels were increased by the overexpression
both in the soluble and insoluble fraction (n=3).
(TIF)
Table S1 Expected DNA fragment sizes of the designed
Southern blot analysis. The digestion with NsiI allowed the
verification of successful 59 homologous recombination. SphI
digestion specifically detected the genomic integration of the CAG
repeat. The digestion with AvrII and SpeI allowed the detection of
the 39 homologous recombination.
(DOC)
Table S2 Primers for the verification of correct 3’ and 5’
integration.
(DOCX)
Table S3 Primers for generation of an internal 3’ probe and
external 5’ probe for Southern Blot analysis.
(DOCX)
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mediated excision.
(DOCX)
Table S5 Expected fragment sizes for the Flp-excision Southern
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